- Home
- Applications
- cancer treatment sarcomatoid carcinoma tumor
Show results for
Refine by
Cancer Treatment Sarcomatoid Carcinoma Tumor Product Applications
40 applications found
4 Ways Digital Can Transform Treatment Selection in Oncology Expert insights on the challenges care teams face in pairing patients with oncology treatments and how digital health solutions can help New and innovative cancer treatments are coming to market faster than ever—a huge win for both patients and care teams. However, with the influx of new treatments also comes an “information avalanche.” Simply put, oncologists are struggling with the sheer volume of information they need to keep ...
ByBrightInsight, Inc based in San Jose, CALIFORNIA (USA)
Simplifying The Complexities of Modern Health ...
ByNantHealth, Inc. based in Morrisville, NORTH CAROLINA (USA)
SNAQ-SEQ ctDNA spike-in standards Liquid biopsies offer the promise of earlier detection and monitoring of cancer patients’ treatment progression. However, as applications increasingly rely on ultra low variant allele frequency detection, NGS-based assays are beset with significantly more noise below 0.5% VAF that increases the rate of false positives. Laboratories looking to implement ctDNA assays need better quality controls that can ensure accurate detection and reporting by variant calling ...
ByAccuGenomics, Inc. based in Wilmington, NORTH CAROLINA (USA)
The development of highly cytotoxic drugs is needed for the success of the treatment in tumor cells. Paradoxically, the high toxicity limits its efficacy and application in vivo, causing damage to non-target organs and severe secondary effects. The use of directed liposomes has allowed the advance of many cancer drugs to preclinical and clinical trials, reducing side effects, and increasing their therapeutic index at the same time. More than 15 cancer liposomed drugs are currently clinically ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Inspire your patients to care for their whole self. Know the composition of their arms and legs with advanced technology for point-of-care segmental ...
ByImpediMed Inc. based in Carlsbad, CALIFORNIA (USA)
Providing physicians with innovative and meaningful assays for the earlier detection of clinically significantly prostate ...
ByMDxHealth based in Irvine, CALIFORNIA (USA)
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibrosis that can be induced by circulating ...
ByEliaz Therapeutics based in Santa Rosa, CALIFORNIA (USA)
PLGA nanospheres have already been successfully used in vitro and in clinical trials. Results show that drugs encapsulated in PLGA nanoparticles have superior accumulation in the tumor environment, reduced tumor size and enhanced inhibition of cell proliferation. This is thanks to increased cell penetration and reduced toxicity of encapsulated compounds. Because of the higher accumulation in tumoral areas PLGA nanoparticles are also useful for cancer diagnosis and imaging which has a key role in clinical oncology ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer ...
ByiRepertoire, Inc. based in Huntsville, ALABAMA (USA)
A system and method for the practice of apheresis employs modules in the system which can be selected for a particular patient to treat particular situations or combinations of difficulties. In one example, Gal-3 mediates a large number of body reactions, and is an effective protector of tumor microenvironments and the like, as well inflammation ...
ByEliaz Therapeutics based in Santa Rosa, CALIFORNIA (USA)
Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer ...
ByiRepertoire, Inc. based in Huntsville, ALABAMA (USA)
We have developed proprietary methods for expressing immunotherapeutic payloads in a highly controlled and specific manner within tumors. IFN-α is a well-known therapeutic that was previously administered systemically for treatment of various cancers but it is currently rarely used because of its systemic toxicity. In the tumor microenvironment, IFN-α exerts its anti-tumor activity both directly by promoting cancer cell apoptosis and inhibiting vascularization and indirectly by restoring anti-tumor ...
ByGenenta Science based in Milano, ITALY
For the world’s leading radiation oncologists, cancer treatment has changed dramatically in recent years. Electron beam technology is becoming more precise, more portable and more efficient. And the interaction and collaboration with surgical teams in the OR has meant that radiation treatment has entered a new era. An era where the procedure is successfully administered in ...
ByIntraOp Medical, Inc. based in Sunnyvale, CALIFORNIA (USA)
Therapeutic apheresis works to remove degenerative, pro-cancer and pro-inflammatory compounds that contribute to the progression of life-threatening illness— allowing the body a chance to deeply detoxify, while enhancing the effects of other therapies and supporting optimal ...
ByEliaz Therapeutics based in Santa Rosa, CALIFORNIA (USA)
Like other nanocarriers, synthetic exosomes can be used to treat different types of cancer successfully, by encapsulating the desired anti-tumoral drug or RNA and enzymes. Several studies have used engineered exosomes from dendritic or macrophage cells to release chemotherapeutic compounds as doxorubicin, paclitaxel miRNA or siRNA to induce antitumoral activity. Rodent mammary carcinoma, mice lung cancer, glioma and pancreatic cancer are just some targeted diseases in preclinical testing using exosome delivery ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Cancer is one of the leading causes of deaths in India and a major public health concern. It is estimated that there are around 1 million new cancer cases every year and as many as 5 lakh deaths occur annually. Around 71% of all cancer deaths in India occur in people 30 to 69 years of age, when adults are very productive. The burden of cancer is expected to further increase due to increase in life expectancy, heavy use of tobacco and other risk factors such as radiation, viruses, ...
ByinDNA Research Labs based in , INDIA
The presence of a nodule in your lung, more commonly known as a mass or “spot” on your lungs, can be quite scary. However, a lung nodule or mass is a lot more common than you might think. Many nodules are benign, meaning that they are not cancer. It is important to know what type of lung nodule you have. ...
ByAuris Health, Inc. based in Redwood City, CALIFORNIA (USA)
Dysregulation of immune cell functions can result in many serious and fatal diseases that require re-modulating the immune cells and restoring their normal response. Monitoring of immune cells while interacting with self-cells, pathogens, and cancer promotes our understanding of immune response or its failure ...
ByTelight based in Brno, CZECH REPUBLIC
The ability to create large, RF lesions has multiple applications in soft tissue and tumor ablation. For example, there is a clear, unmet need in the market for the treatment of liver cancer. ...
ByThermedical, Inc. based in Waltham, MASSACHUSETTS (USA)
The IntraOp® Mobetron® is the most comprehensive electron therapy linear accelerator system with applications in intraoperative radiotherapy (IORT) and non-invasive treatment of skin cancer. Now Mobetron is the first to offer ultra-high dose rate electron therapy for preclinical and investigational studies of FLASH radiotherapy on an established clinical radiotherapy platform. IntraOp’s advanced technology ushers in a new paradigm for cancer treatment by providing researchers an approach not possible ...
ByIntraOp Medical, Inc. based in Sunnyvale, CALIFORNIA (USA)